Ginkgo Bioworks Inc. (DNA)
Ginkgo Bioworks Statistics
Share Statistics
Ginkgo Bioworks has 58.53M shares outstanding. The number of shares has increased by -97.51% in one year.
| 58.53M |
| -97.51% |
| -4.25% |
| 62.64% |
| n/a |
| 3,202 |
| 0.26% |
Short Selling Information
The latest short interest is 11.49M, so 19.64% of the outstanding shares have been sold short.
| 11.49M |
| 19.64% |
| 25.47% |
| 10.14 |
Valuation Ratios
The PE ratio is -0.93 and the forward PE ratio is -1.81. Ginkgo Bioworks's PEG ratio is 0.02.
| -0.93 |
| -1.81 |
| 2.24 |
| 1.1 |
| 0.71 |
| -1.33 |
| 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ginkgo Bioworks.
| n/a |
| n/a |
| n/a |
| n/a |
Financial Position
The company has a current ratio of 5.62, with a Debt / Equity ratio of 0.65.
| 5.62 |
| 5.62 |
| 0.65 |
| -0.97 |
| -1.22 |
| -5954.86 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| n/a |
| n/a |
| n/a |
| $272,233.81 |
| $-655,910.07 |
| 834 |
| 0.16 |
| n/a |
Taxes
| -479K |
| 0.09% |
Stock Price Statistics
The stock price has increased by -63.18% in the last 52 weeks. The beta is 1.26, so Ginkgo Bioworks's price volatility has been higher than the market average.
| 1.26 |
| -63.18% |
| 7.24 |
| 8.56 |
| 52.17 |
| 1,232,011 |
Income Statement
In the last 12 months, Ginkgo Bioworks had revenue of 227.04M and earned -547.03M in profits. Earnings per share was -10.54.
| 227.04M |
| 188.49M |
| -559.76M |
| -547.03M |
| -484.39M |
| -547.41M |
| -10.54 |
Balance Sheet
The company has 561.57M in cash and 467.73M in debt, giving a net cash position of 93.84M.
| 561.57M |
| 467.73M |
| 93.84M |
| -5.84B |
| 1.29B |
| 448.87M |
Cash Flow
In the last 12 months, operating cash flow was -319.58M and capital expenditures -62.54M, giving a free cash flow of -382.13M.
| -319.58M |
| -62.54M |
| -382.13M |
| -7.36 |
Margins
Gross margin is 83.02%, with operating and profit margins of -246.54% and -240.94%.
| 83.02% |
| -246.54% |
| -241.15% |
| -240.94% |
| -213.35% |
| -246.54% |
| -168.31% |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Analyst Forecast
The average price target for DNA is $10, which is 32.1% higher than the current price. The consensus rating is "Sell".
| $10 |
| 32.1% |
| Sell |
| 3 |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| n/a |
| n/a |
| n/a |
| n/a |
Stock Splits
The last stock split was on Aug 20, 2024. It was a backward split with a ratio of 1:40.
| Aug 20, 2024 |
| backward |
| 1:40 |
Scores
| -6.56 |
| 3 |